Viread will be marketed as a therapy for chronic disease in adults.
Gilead Sciences received FDA sanction for its chronic hepatitis B treatment Viread®. The drug works by blocking HBV DNA polymerase, the enzyme that is necessary for the virus to replicate in liver cells.
Viread will be marketed as a once-daily regimen. Earlier this year, it was approved for chronic hepatitis B in the EU, Turkey, Australia, and New Zealand. A marketing application is currently pending in Canada, reports Gilead.
Viread is also indicated for HIV infection in adults. It has been on the U.S. market since 2001. The hepatitis B approval expands Gilead’s hepatic health franchise, which also includes Hepsera for chronic hepatitis B.
